波士顿咨询：2023生物制药的价值之路与生成式AI研究报告（中译版）（12页）.pdf

1、 2023 Boston Consulting Group1 There is little question that generative AI(GenAI)will transform how biopharma companies develop,produce,and commercialize new treatments.We have already seen big reductions in drug R&Dtimelines.The potential across the rest of the value chain is clear.But implementing

2、 GenAI is not easy in a complex industry with intensive regulatory oversight.GenAIssprawling capabilities present challenges with respect to where and how it should be applied,whenBiopharmas Path to Value withGenerative AIOCTOBER 09,2023 By Julius Neiser,Krishna Srikumar,Myrto Lee,Camille Engel,Gang

3、a Kannan,and Dhruv JayanthREADING TIME:12 MIN 2023 Boston Consulting Group2and how to scale up its use,and how to manage the resulting large-scale change.Establishing theconditions for rapid experimentation and scaling requires a tight convergence of technology andstrategy,with deliberate choices gr

4、ounded in the circumstances of the individual organization.An Abundance of Potential,Choices,and ConstraintsMuch of GenAIs potential grows out of three game-changing characteristics:The ability to process(and learn from)terabytes of structured and unstructured data(such asacademic literature,clinica

5、l-trial information,batch records,quality investigation reports,electronic medical records,and claims databases)The ability to generate completely new content:text,media(image,speech,and video),design,and codeIntuitive,conversational user interfaces that reduce AIs adoption hurdles,making the techno

6、logywidely accessible 2023 Boston Consulting Group3In biopharma,GenAI can be applied at all stages of the value chainoperations,commercial andmedical affairs,and corporate functions,in addition to R&Dwith the potential to substantiallyincrease efficiency and effectiveness by transforming existing pr